{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:27:37Z","timestamp":1788449257310,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.urolonc.2024.06.010","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:30:45Z","timestamp":1722475845000},"page":"450.e13-450.e22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method?"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8216-1753","authenticated-orcid":false,"given":"Fatih","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5300-8071","authenticated-orcid":false,"given":"Suleyman","family":"Sagir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.06.010_bib0001","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424. https:\/\/doi.org\/10.3322\/caac.21492","DOI":"10.3322\/caac.21492"},{"key":"10.1016\/j.urolonc.2024.06.010_bib0002","unstructured":"SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed 23 January 2024."},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.010_bib0003","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.21037\/tau.2019.09.38","article-title":"Transurethral resection of bladder tumour (TURBT)","volume":"9","author":"Kim","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.010_bib0004","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.010_bib0005","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.06.010_bib0007","unstructured":"Collage of American Pathologists. Protocol for the examination of biopsy and transurethral resection of bladder tumor (TURBT) specimens from patients with carcinoma of the urinary bladder, https:\/\/www.cap.org\/protocols-and-guidelines\/cancer-reporting-tools\/cancer-protocol-templates; 2023 [Protocol Posting Date: September 2023]. Accessed 25 December 2023."},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.010_bib0008","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/2326-6066.CIR-18-0758","article-title":"The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes","volume":"7","author":"Pfannstiel","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"10.1016\/j.urolonc.2024.06.010_bib0009","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.3390\/cancers14153748","article-title":"Tertiary lymphoid structures as mediators of immunotherapy response","volume":"14","author":"Vaghjiani","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2024.06.010_bib0010","doi-asserted-by":"crossref","unstructured":"Dijk Nv, Gil-Jimenez A, Silina K, Montfoort MLv, Einerhand S, Jonkman L, et al. The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer 2021;12:793964. https:\/\/doi.org\/10.3389\/fimmu.2021.793964","DOI":"10.3389\/fimmu.2021.793964"},{"issue":"7791","key":"10.1016\/j.urolonc.2024.06.010_bib0011","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"7791","key":"10.1016\/j.urolonc.2024.06.010_bib0012","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.010_bib0013","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.010_bib0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","article-title":"Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling","volume":"179","author":"Coppola","year":"2011","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1915574","article-title":"Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer","volume":"10","author":"Zhou","year":"2021","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.010_bib0016","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-022-03310-5","article-title":"Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma","volume":"72","author":"Liu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.010_bib0017","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41416-024-02598-7","article-title":"Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer","volume":"130","author":"Zhang","year":"2024","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.010_bib0018","first-page":"64","article-title":"Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience","volume":"9","author":"Gulinac","year":"2020","journal-title":"Am J Clin Exp Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2024.06.010_bib0019","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/modpathol.3800517","article-title":"Prognosticators of melanoma, the melanoma report, and the sentinel lymph node","volume":"19","author":"Crowson","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2024.06.010_bib0020","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/srep00765","article-title":"12-chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?","volume":"2","author":"Messina","year":"2012","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.urolonc.2024.06.010_bib0021","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00262-019-02407-8","article-title":"The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer","volume":"68","author":"Sofopoulos","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.010_bib0022","doi-asserted-by":"crossref","first-page":"e006425","DOI":"10.1136\/jitc-2022-006425","article-title":"Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.010_bib0023","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-023-02235-9","article-title":"Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors","volume":"128","author":"Hayashi","year":"2023","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.010_bib0024","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/21681805.2016.1163616","article-title":"Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes","volume":"50","author":"Bos","year":"2016","journal-title":"Scand Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.010_bib0025","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","article-title":"Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma","volume":"76","author":"Ding","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.010_bib0026","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.010_bib0027","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/ni.3290","article-title":"Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma","volume":"16","author":"Finkin","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2024.06.010_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166497","article-title":"Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma","volume":"14","author":"Shang","year":"2023","journal-title":"Front Immunol"},{"issue":"6349","key":"10.1016\/j.urolonc.2024.06.010_bib0029","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts the response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.010_bib0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.urolonc.2024.06.010_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.145534","article-title":"Genomic and immunological features of microsatellite instability in colon cancer","volume":"781","author":"Luo","year":"2021","journal-title":"Gene"},{"issue":"8","key":"10.1016\/j.urolonc.2024.06.010_bib0032","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.010_bib0033","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.urolonc.2019.12.012","article-title":"MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass","volume":"38","author":"Fraune","year":"2020","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.010_bib0034","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.eururo.2006.04.010","article-title":"Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer","volume":"50","author":"Burger","year":"2006","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.010_bib0035","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.11109","article-title":"Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability","volume":"105","author":"Catto","year":"2003","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.010_bib0036","first-page":"2117","article-title":"Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy","volume":"26","author":"Tural","year":"2021","journal-title":"J BUON"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.010_bib0037","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13000-021-01168-2","article-title":"Morphological predictors for microsatellite instability in urothelial carcinoma","volume":"16","author":"Sobrino-Reig","year":"2021","journal-title":"Diagn Pathol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.010_bib0038","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/iju.15370","article-title":"Clinical features and oncological outcomes of bladder cancer microsatellite instability","volume":"31","author":"Nagakawa","year":"2024","journal-title":"Int J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.010_bib0039","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S2468-1253(24)00091-8","article-title":"Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis","volume":"9","author":"Wankhede","year":"2024","journal-title":"Lancet Gastro Hepatol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.06.010_bib0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10064","key":"10.1016\/j.urolonc.2024.06.010_bib0041","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.010_bib0042","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/BLC-170120","article-title":"Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer","volume":"3","author":"Koti","year":"2017","journal-title":"Bladder Canc"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.010_bib0043","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1093\/oncolo\/oyad283","article-title":"Presence, subtypes, and prognostic significance of tertiary lymphoid structures in urothelial carcinoma of the bladder","volume":"29","author":"Ma","year":"2023","journal-title":"Oncologist"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392400509X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392400509X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T03:33:39Z","timestamp":1731728019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392400509X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S107814392400509X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}